Chemed Corp: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on Apr 28, 2023 and accepted by EDGAR at Apr 28, 2023, 09:29 ET.
Management's discussion and analysis
As filed, 29,940 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Executive Summary
We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, Independent Contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.
The vast majority of the Company’s operations are located in the United States. As both operations are service companies, our employees are the most critical resource of the Company. We have very little or no exposure related to customers, vendors, or employees in other regions of the world.
The following is a summary of the key operating results (in thousands except per share amounts):
| Three months ended March 31, 2023 | 2022 | |
|---|---|---|
| Service revenues and sales | $560,157 | $530,549 |
| Net income | $54,121 | $64,169 |
| Diluted EPS | $3.58 | $4.22 |
| Adjusted net income | $72,867 | $72,780 |
| Adjusted diluted EPS | $4.82 | $4.79 |
| Adjusted EBITDA | $111,033 | $110,208 |
| Adjusted EBITDA as a % of revenue | 19.8% | 20.8% |
Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 27-28.
For the three months ended March 31, 2023, the increase in consolidated service revenues and sales was driven by a 7.9% increase at Roto-Rooter and a 3.8% increase at VITAS. The increase in service revenues at Roto-Rooter was driven mainly by an increase in plumbing, excavation, and water restoration. The increase in service revenues at VITAS is comprised primarily of a 3.0% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.9%, partially offset by 200-basis points as a result of CMS reimplementing the 2.0% sequestration cut that was suspended at the start of the pandemic in 2020. Acuity mix shift had minimal impact in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes negatively impacted revenue growth by 10-basis points.
The pandemic has resulted in a significant shortage of licensed healthcare workers industry wide. VITAS has not been immune to this shortage. As a result, on July 1, 2022, VITAS implemented a hiring and retention bonus program for its licensed healthcare workers. It is a temporary program intended to help VITAS attract and retain licensed healthcare workers in light of the pandemic induced healthcare worker shortage. An eligible employee must continue in employment for a period of one-year from July 1st to receive a bonus. Additionally, employees hired between July 1, 2022 and June 30, 2023 are eligible if they continue employment for a one-year period from their hire date. The Company accrued $10.9 million in the first quarter of 2023 related to this retention bonus program. See page 29 for additional VITAS operating metrics.
While significant continuing issues related to the COVID-19 pandemic appear to be over or materially mitigated, we will continue to monitor any impact on our business including employees, customers, patients, and supply vendors.
While many companies have been adversely impacted by the banking crisis of March 2023, we do not anticipate any significant financial impact. The vast majority of our funds are in the two largest banks in the United States, as measured by total assets.
Management anticipates providing updated 2023 earnings guidance as part of the June 30, 2023, earnings press release.
On June 28, 2022, we replaced our existing credit facility with a fifth amended and restated Credit Agreement (“2022 Credit Facilities”). Terms of the 2022 Credit Facilities consist of a five-year $450.0 million revolver as well as a five-year $100.0 million term loan. Principal payments of $1.25 million on the term loan are due on the last day of each fiscal quarter, with a final payment due at the end of the agreement. The 2022 Credit Facilities have a floating interest rate that is generally SOFR plus an additional tiered rate which varies based on our current leverage ratio. As of March 31, 2023, the interest rate is SOFR plus 100 basis points. The 2022 Credit Facilities includes an expansion feature that provides the Company the opportunity to increase its revolver and or term loan by an additional $250.0 million.
We made prepayments totaling $75.0 million in the first quarter of 2023, on the $100.0 million term loan. We plan to pay the remaining balance of $21.3 million on April 28, 2023. There are no prepayment penalties associated with this repayment. This will reduce the borrowing capacity of the 2022 Credit Facilities from $550.0 million to $450.0 million.
We have issued $45.3 million in standby letters of credit as of March 31, 2023, mainly for insurance purposes. Issued letters of credit reduce our available credit under the 2022 Credit Facilities. As of March 31, 2023, we have approximately $404.7 million of unused lines of credit available and are eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.
We anticipate that our operating income and cash flows will be sufficient to operate our business and meet any commitments for the foreseeable future.
Financial Condition
Liquidity and Capital Resources
Material changes in the balance sheet accounts from December 31, 2022 to March 31, 2023 include the following:
A $14.4 million increase in accounts receivable due to timing of receipts. See discussion below.
A $7.9 million decrease in prepaid income taxes due to timing of payments.
An $11.2 million increase in income tax due to timing of payments.
A $37.2 million decline in accrued compensation due to payment of 2022 bonuses in the first quarter of 2023.
An $8.3 million increase in other current liabilities due mainly to the healthcare worker retention bonus program at VITAS.
A $76.3 million decrease in long-term debt due to repayments.
Net cash provided by operating activities decreased $40.6 million from March 31, 2022 to March 31, 2023. The main drivers of the decrease are a decrease in net income of $10.0 million, and a $33.9 million increase in accounts receivable. Significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $42.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two-year period, as cash flow variations in one year are offset in the following year.
Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.
Commitments and Contingencies
Collectively, the terms of the 2022 Credit Facilities require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of March 31, 2023 and anticipate remaining in compliance throughout the foreseeable future.
We are subject to various lawsuits and claims in the normal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the existence of regulatory and legal actions when we believe it is reasonably possible that a loss could occur in connection with the specific action. In most instances, we are unable to make a reasonable estimate of any reasonably possible liability due to the uncertainty of the outcome and stage of litigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.
See Note 10 in the Notes to the Unaudited Consolidated Financial Statements in Item 1 above for a description of current material legal matters.
Results of Operations
Three months ended March 31, 2023 versus 2022 - Consolidated Results
Our service revenues and sales for the first quarter of 2023 increased 5.6% versus services and sales revenues for the first quarter of 2022. Of this increase, an $18.3 million increase was attributable to Roto-Rooter, and an $11.3 million increase was attributable to VITAS. The following chart shows the components of revenue by operating segment (in thousands):
| VITAS | Three months ended March 31, 2023 | 2022 | Increase/(Decrease) Percent |
|---|---|---|---|
| Routine homecare | $267,050 | $257,636 | 3.7 |
| Continuous care | 19,941 | 19,578 | 1.9 |
| General inpatient | 29,093 | 26,570 | 9.5 |
| Other | 3,021 | 3,007 | 0.5 |
| Subtotal | 319,105 | 306,791 | 4.0 |
| Medicare cap adjustment | (2,750) | (2,500) | (10.0) |
| Room and board - net | (2,769) | (2,117) | (30.8) |
| Implicit price concessions | (3,108) | (2,985) | (4.1) |
| Net revenue | $310,478 | $299,189 | 3.8 |
| Roto-Rooter | |||
| Drain cleaning | $66,489 | $66,687 | (0.3) |
| Plumbing | 50,453 | 47,672 | 5.8 |
| Excavation | 59,576 | 55,188 | 8.0 |
| Other | 193 | 165 | 17.0 |
| Subtotal - short term core | 176,711 | 169,712 | 4.1 |
| Water restoration | 50,762 | 40,360 | 25.8 |
| Independent contractors | 23,300 | 21,418 | 8.8 |
| Outside franchisee fees | 1,351 | 1,317 | 2.6 |
| Other | 4,745 | 4,191 | 13.2 |
| Gross revenue | 256,869 | 236,998 | 8.4 |
| Implicit price concessions | (7,190) | (5,638) | (27.5) |
| Net revenue | 249,679 | 231,360 | 7.9 |
| Total Revenues | $560,157 | $530,549 | 5.6 |
Days of care at VITAS during the quarters were as follows:
| Three months ended March 31, 2023 | 2022 | Increase/(Decrease) Percent | |
|---|---|---|---|
| Routine homecare | 1,286,437 | 1,258,672 | 2.2 |
| Nursing home | 265,429 | 248,468 | 6.8 |
| Respite | 5,760 | 5,368 | 7.3 |
| Subtotal routine homecare and respite | 1,557,626 | 1,512,508 | 3.0 |
| General inpatient | 26,369 | 24,587 | 7.2 |
| Continuous care | 20,686 | 21,082 | (1.9) |
| Total days of care | 1,604,681 | 1,558,177 | 3.0 |
The increase in service revenues at VITAS is comprised primarily of a 3.0% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.9%, partially offset by 200-basis points as a result of CMS reimplementing the 2.0% sequestration cut that was suspended at the start of the pandemic in 2020. Acuity mix shift had minimal impact in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes negatively impacted revenue growth by 10-basis points.
The increase in plumbing revenues for the first quarter of 2023 versus 2022 is attributable to a 13.0% increase in price and service mix shift offset by a 7.2% decrease in job count. Excavation and water restoration jobs are generally sold as a result of initial calls from customers regarding drain cleaning issues. As a result, the 8.0% increase in excavation revenue and the 25.8% increase in water restoration revenue are mainly a function of the numbers and size of drain cleaning issues we encounter on a quarterly basis. Independent Contractor revenue increased 8.8% due mainly to increased expansion into water restoration.
The consolidated gross margin was 33.8% in the first quarter of 2023 as compared with 36.6% in the first quarter of 2022. On a segment basis, VITAS’ gross margin was 18.3% in the first quarter of 2023 as compared with 24.0%, in the first quarter of 2022. The decrease in gross margin at VITAS is mostly the result of the $10.9 million expense recorded in the first quarter of 2023 for the licensed healthcare worker retention bonus program. The Roto-Rooter segment’s gross margin was 53.1% for the first quarter of 2023 as compared with 52.8% in the first quarter of 2022.
Selling, general and administrative expenses (“SG&A”) comprise (in thousands):
| Three months ended March 31, 2023 | 2022 | |
|---|---|---|
| SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts | $97,902 | $92,578 |
| Impact of market value adjustments related to assets held in deferred compensation trusts | (321) | (3,934) |
| Long-term incentive compensation | 2,514 | 1,310 |
| Total SG&A expenses | $100,095 | $89,954 |
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first quarter of 2023 were up 5.8% when compared to the first quarter of 2022. This increase was mainly a result of variable selling and general administrative expenses and overall inflation-related cost increases, including salary at both operating units.
Other (expense)/income – net comprise (in thousands):
| Three months ended March 31, 2023 | 2022 | |
|---|---|---|
| Market value adjustment on assets held in deferred compensation trusts | $(321) | $(3,934) |
| Interest income | 150 | 73 |
| Other | 68 | (1) |
| Total expense - net | $(103) | $(3,862) |
Our effective tax rate reconciliation is as follows (in thousands):
| Three months ended March 31, 2023 | 2022 | |
|---|---|---|
| Income tax provision calculated at the statutory federal rate | $14,945 | $17,787 |
| Stock compensation tax benefits | (1,650) | (1,441) |
| State and local income taxes | 2,940 | 3,241 |
| Other--net | 809 | 946 |
| Income tax provision | $17,044 | $20,533 |
| Effective tax rate | 23.9% | 24.2% |
Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):
| VITAS | Three months ended March 31, 2023 | 2022 |
|---|---|---|
| Licensed healthcare worker retention bonus | $(8,144) | $- |
| Direct costs related to COVID-19 | - | (292) |
| Roto-Rooter | ||
| Amortization of reacquired franchise agreements | (1,729) | (1,729) |
| Litigation settlements | (1,290) | - |
| Direct costs related to COVID-19 | - | (706) |
| Corporate | ||
| Stock option expense | (7,010) | (6,166) |
| Long-term incentive compensation | (2,223) | (1,159) |
| Excess tax benefits on stock compensation | 1,650 | 1,441 |
| Total | $(18,746) | $(8,611) |
Three months ended March 31, 2023 versus 2022 - Segment Results
Net income/(loss) for the first quarter of 2023 versus the first quarter of 2022 by segment (in thousands):
| Three months ended March 31, 2023 | 2022 | |
|---|---|---|
| VITAS | $24,764 | $36,481 |
| Roto-Rooter | 47,653 | 43,937 |
| Corporate | (18,296) | (16,249) |
| $54,121 | $64,169 |
VITAS’ after-tax earnings decreased primarily due to the $8.1 million in after-tax expense related to VITAS’ licensed healthcare worker retention bonus program, as well as the reimplementation of the 2.0% sequestration cut that was suspended at the start of the pandemic in 2020, in the first quarter of 2023 when compared to the first quarter of 2022. After-tax earnings as a percent of revenue at VITAS in the first quarter of 2023 was 8.0% as compared to 12.2% in the first quarter of 2022.
Roto-Rooter’s net income was impacted in the first quarter of 2023 compared to the first quarter of 2022 primarily by higher revenue. After-tax earnings as a percent of revenue at Roto-Rooter in the first quarter of 2023 was 19.1%, as compared to 19.0% in the first quarter of 2022.
After-tax Corporate expenses for the first quarter of 2023 increased 12.6% when compared to 2022 due to a $1.9 million increase in stock-based compensation.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED MARCH 31, 2023
(in thousands)(unaudited)
| 2023 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
|---|---|---|---|---|
| Service revenues and sales | $310,478 | $249,679 | $- | $560,157 |
| Cost of services provided and goods sold | 253,654 | 117,051 | - | 370,705 |
| Selling, general and administrative expenses | 23,336 | 60,813 | 15,946 | 100,095 |
| Depreciation | 4,958 | 7,312 | 16 | 12,286 |
| Amortization | 26 | 2,487 | - | 2,513 |
| Other operating expense | 12 | 1,727 | - | 1,739 |
| Total costs and expenses | 281,986 | 189,390 | 15,962 | 487,338 |
| Income/(loss) from operations | 28,492 | 60,289 | (15,962) | 72,819 |
| Interest expense | (50) | (133) | (1,368) | (1,551) |
| Intercompany interest income/(expense) | 4,648 | 2,743 | (7,391) | - |
| Other (expense)/ income—net | 189 | 29 | (321) | (103) |
| Income/(expense) before income taxes | 33,279 | 62,928 | (25,042) | 71,165 |
| Income taxes | (8,515) | (15,275) | 6,746 | (17,044) |
| Net income/(loss) | $24,764 | $47,653 | $(18,296) | $54,121 |
| (a) The following amounts are included in net income (in thousands): | ||||
| Chemed | ||||
| VITAS | Roto-Rooter | Corporate | Consolidated | |
| Pretax benefit/(cost): | ||||
| Licensed healthcare worker retention bonus | $(10,916) | $- | $- | $(10,916) |
| Stock option expense | - | - | (8,482) | (8,482) |
| Long-term incentive compensation | - | - | (2,514) | (2,514) |
| Amortization of reacquired franchise agreements | - | (2,352) | - | (2,352) |
| Litigation settlements | - | (1,756) | - | (1,756) |
| Total | $(10,916) | $(4,108) | $(10,996) | $(26,020) |
| Chemed | ||||
| VITAS | Roto-Rooter | Corporate | Consolidated | |
| After-tax benefit/(cost): | ||||
| Licensed healthcare worker retention bonus | $(8,144) | $- | $- | $(8,144) |
| Stock option expense | - | - | (7,010) | (7,010) |
| Long-term incentive compensation | - | - | (2,223) | (2,223) |
| Amortization of reacquired franchise agreements | - | (1,729) | - | (1,729) |
| Litigation settlements | - | (1,290) | - | (1,290) |
| Excess tax benefits on stock compensation | - | - | 1,650 | 1,650 |
| Total | $(8,144) | $(3,019) | $(7,583) | $(18,746) |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED MARCH 31, 2022
(in thousands)(unaudited)
| 2022 (a) | VITAS | Roto-Rooter Corporate | Chemed Consolidated |
|---|---|---|---|
| Service revenues and sales | $299,189 | $231,360 $- | $530,549 |
| Cost of services provided and goods sold | 227,240 | 109,312 - | 336,552 |
| Selling, general and administrative expenses | 22,453 | 56,954 10,547 | 89,954 |
| Depreciation | 5,551 | 6,569 18 | 12,138 |
| Amortization | 24 | 2,494 - | 2,518 |
| Other operating expense/(income) | (148) | 161 - | 13 |
| Total costs and expenses | 255,120 | 175,490 10,565 | 441,175 |
| Income/(loss) from operations | 44,069 | 55,870 (10,565) | 89,374 |
| Interest expense | (52) | (115) (643) | (810) |
| Intercompany interest income/(expense) | 4,656 | 2,176 (6,832) | - |
| Other (expense)/income—net | 37 | 35 (3,934) | (3,862) |
| Income/(expense) before income taxes | 48,710 | 57,966 (21,974) | 84,702 |
| Income taxes | (12,229) | (14,029) 5,725 | (20,533) |
| Net income/(loss) | $36,481 | $43,937 $(16,249) | $64,169 |
| (a) The following amounts are included in net income (in thousands): | |||
| Chemed | |||
| VITAS | Roto-Rooter Corporate | Consolidated | |
| Pretax benefit/(cost): | |||
| Stock option expense | $- | $$ (7,451) | $(7,451) |
| Amortization of reacquired franchise agreements | - | (2,352) - | (2,352) |
| Direct costs related to COVID-19 | (391) | (961) - | (1,352) |
| Long-term incentive compensation | - | - (1,310) | (1,310) |
| Total | $(391) | $(3,313) $(8,761) | $(12,465) |
| Chemed | |||
| VITAS | Roto-Rooter Corporate | Consolidated | |
| After-tax benefit/(cost): | |||
| Stock option expense | $- | $- $(6,166) | $(6,166) |
| Amortization of reacquired franchise agreements | - | (1,729) - | (1,729) |
| Long-term incentive compensation | - | - (1,159) | (1,159) |
| Direct costs related to COVID-19 | (292) | (706) - | (998) |
| Excess tax benefits on stock compensation | - | - 1,441 | 1,441 |
| Total | $(292) | $(2,435) $(5,884) | $(8,611) |
Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA
(in thousands)
| Chemed Corporation and Subsidiary Companies For the three months ended March 31, 2023 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
|---|---|---|---|---|
| Net income/(loss) | $24,764 | $47,653 | $(18,296) | $54,121 |
| Add/(deduct): | ||||
| Interest expense | 50 | 133 | 1,368 | 1,551 |
| Income taxes | 8,515 | 15,275 | (6,746) | 17,044 |
| Depreciation | 4,958 | 7,312 | 16 | 12,286 |
| Amortization | 26 | 2,487 | - | 2,513 |
| EBITDA | 38,313 | 72,860 | (23,658) | 87,515 |
| Add/(deduct): | ||||
| Intercompany interest expense/(income) | (4,648) | (2,743) | 7,391 | - |
| Interest income | (121) | (29) | - | (150) |
| Licensed healthcare retention bonus | 10,916 | - | - | 10,916 |
| Stock option expense | - | - | 8,482 | 8,482 |
| Long-term incentive compensation | - | - | 2,514 | 2,514 |
| Litigation settlements | - | 1,756 | - | 1,756 |
| Adjusted EBITDA | $44,460 | $71,844 | $(5,271) | $111,033 |
| Chemed | ||||
| For the three months ended March 31, 2022 | VITAS | Roto-Rooter | Corporate | Consolidated |
| Net income/(loss) | $36,481 | $43,937 | $(16,249) | $64,169 |
| Add/(deduct): | ||||
| Interest expense | 52 | 115 | 643 | 810 |
| Income taxes | 12,229 | 14,029 | (5,725) | 20,533 |
| Depreciation | 5,551 | 6,569 | 18 | 12,138 |
| Amortization | 24 | 2,494 | - | 2,518 |
| EBITDA | 54,337 | 67,144 | (21,313) | 100,168 |
| Add/(deduct): | ||||
| Intercompany interest expense/(income) | (4,656) | (2,176) | 6,832 | - |
| Interest income | (37) | (36) | - | (73) |
| Stock option expense | - | - | 7,451 | 7,451 |
| Direct costs related to COVID-19 | 391 | 961 | - | 1,352 |
| Long-term incentive compensation | - | - | 1,310 | 1,310 |
| Adjusted EBITDA | $50,035 | $65,893 | $(5,720) | $110,208 |
RECONCILIATION OF ADJUSTED NET INCOME
(in thousands, except per share data)(unaudited)
| Three Months Ended March 31, 2023 | 2022 | |
|---|---|---|
| Net income as reported | $54,121 | $64,169 |
| Add/(deduct) pre-tax cost of: | ||
| Licensed healthcare worker retention bonus | 10,916 | - |
| Stock option expense | 8,482 | 7,451 |
| Long-term incentive compensation | 2,514 | 1,310 |
| Amortization of reacquired franchise agreements | 2,352 | 2,352 |
| Litigation settlements | 1,756 | - |
| Direct costs related to COVID-19 | - | 1,352 |
| Add/(deduct) tax impacts: | ||
| Tax impact of the above pre-tax adjustments (1) | (5,624) | (2,413) |
| Excess tax benefits on stock compensation | (1,650) | (1,441) |
| Adjusted net income | $72,867 | $72,780 |
| Diluted Earnings Per Share As Reported | ||
| Net income | $3.58 | $4.22 |
| Average number of shares outstanding | 15,110 | 15,192 |
| Adjusted Diluted Earnings Per Share | ||
| Adjusted net income | $4.82 | $4.79 |
| Adjusted average number of shares outstanding | 15,110 | 15,192 |
| (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)
| OPERATING STATISTICS Net revenue ($000) | Three Months Ended March 31, 2023 | 2022 |
|---|---|---|
| Homecare | $267,050 | $257,636 |
| Inpatient | 29,093 | 26,570 |
| Continuous care | 19,941 | 19,578 |
| Other | 3,021 | 3,007 |
| Subtotal | $319,105 | $306,791 |
| Room and board, net | (2,769) | (2,117) |
| Contractual allowances | (3,108) | (2,985) |
| Medicare cap allowance | (2,750) | (2,500) |
| Total | $310,478 | $299,189 |
| Net revenue as a percent of total before Medicare cap allowances | ||
| Homecare | 83.7% | 84.0% |
| Inpatient | 9.1 | 8.7 |
| Continuous care | 6.2 | 6.4 |
| Other | 1.0 | 0.9 |
| Subtotal | 100.0 | 100.0 |
| Room and board, net | (0.8) | (0.7) |
| Contractual allowances | (1.0) | (1.0) |
| Medicare cap allowance | (0.9) | (0.8) |
| Total | 97.3% | 97.5% |
| Days of care | ||
| Homecare | 1,286,437 | 1,258,672 |
| Nursing home | 265,429 | 248,468 |
| Respite | 5,760 | 5,368 |
| Subtotal routine homecare and respite | 1,557,626 | 1,512,508 |
| Inpatient | 26,369 | 24,587 |
| Continuous care | 20,686 | 21,082 |
| Total | 1,604,681 | 1,558,177 |
| Number of days in relevant time period | 90 | 90 |
| Average daily census (days) | ||
| Homecare | 14,294 | 13,985 |
| Nursing home | 2,949 | 2,761 |
| Respite | 64 | 60 |
| Subtotal routine homecare and respite | 17,307 | 16,806 |
| Inpatient | 293 | 273 |
| Continuous care | 230 | 234 |
| Total | 17,830 | 17,313 |
| Total Admissions | 16,179 | 16,530 |
| Total Discharges | 15,405 | 16,862 |
| Average length of stay (days) | 99.9 | 104.8 |
| Median length of stay (days) | 15.0 | 14.0 |
| ADC by major diagnosis | ||
| Cerebro | 41.8% | 36.7% |
| Neurological | 19.3 | 22.9 |
| Cancer | 10.5 | 11.1 |
| Cardio | 16.0 | 15.9 |
| Respiratory | 7.3 | 7.4 |
| Other | 5.1 | 6.0 |
| Total | 100.0% | 100.0% |
| Admissions by major diagnosis | ||
| Cerebro | 26.4 | 22.9% |
| Neurological | 10.7 | 12.9 |
| Cancer | 24.7 | 24.9 |
| Cardio | 16.2 | 14.1 |
| Respiratory | 10.9 | 11.1 |
| Other | 11.1 | 14.1 |
| Total | 100.0% | 100.0% |
| Estimated uncollectible accounts as a percent of revenues | 1.0% | 1.0% |
| Accounts receivable -- | ||
| Days of revenue outstanding- excluding unapplied Medicare payments | 34.7 | 33.6 |
| Days of revenue outstanding- including unapplied Medicare payments | 29.2 | 23.9 |
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information
Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Market risk
As filed, 586 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At March 31, 2023, the Company had $21.3 million of variable rate debt outstanding. For each $10 million borrowed under the credit facility, an increase or decrease of 100 basis points (1%), increases or decreases the Company’s annual interest expense by $100,000.
The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.
Controls and procedures
As filed, 900 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 141 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $310.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $370.7m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $100.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | $72.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $1.6m | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $17.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | $54.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | $3.58 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | $3.62 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 15,110,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | $60.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $17.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2023-01-01 to 2023-03-31 | $5.7m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2023-03-31 | $58.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $262.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $1.43bn | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $283.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $551.1m | us-gaap:Liabilities |
| Long-term debt | At period end2023-03-31 | $16.3m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-03-31 | $5.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-03-31 | $880.1m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2023-03-31 | 15,019,778 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001562762-23-000183. Last ingested by Listed: Nov 14, 2026, 12:29 ET. Listed shows no prices and gives no investment advice.